All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study

Treatment options for patients with hepatitis C virus (HCV) genotype 3 infection are limited, with the currently approved all-oral regimens requiring 24-week treatment and the addition of ribavirin (RBV). This phase III study (ALLY-3; http://ClinicalTrials.gov: NCT02032901) evaluated the 12-week reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelson, David R, Cooper, James N, Lalezari, Jacob P, Lawitz, Eric, Pockros, Paul J, Gitlin, Norman, Freilich, Bradley F, Younes, Ziad H, Harlan, William, Ghalib, Reem, Oguchi, Godson, Thuluvath, Paul J, Ortiz-Lasanta, Grisell, Rabinovitz, Mordechai, Bernstein, David, Bennett, Michael, Hawkins, Trevor, Ravendhran, Natarajan, Sheikh, Aasim M, Varunok, Peter, Kowdley, Kris V, Hennicken, Delphine, McPhee, Fiona, Rana, Khurram, Hughes, Eric A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2015
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409820/
https://www.ncbi.nlm.nih.gov/pubmed/25614962
http://dx.doi.org/10.1002/hep.27726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409820/
https://www.ncbi.nlm.nih.gov/pubmed/25614962
http://dx.doi.org/10.1002/hep.27726

Ejemplares similares